Sanofi reorganizes its R&D to become a champion of immunology. The pharmaceutical group is putting an end to some of its oncology projects, which have not been successful.
A decision which will result in the elimination of 330 positions in France. “We must reprioritize our portfolio to be able to invest more in immunology,” explains Audrey Derveloy, president of Sanofi France. The French pharmaceutical laboratory announced to union organizations on March 28 its intention to cut 331 positions in its research and development teams dedicated to oncologist.